
APPENDIX VI

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Establishment of our Company

Our Company was established as a limited liability company in the PRC on November 14, 2007 and was converted into a joint stock company with limited liability on 26 November 2025 under the laws of the PRC. Our registered office is located at 1001, No. 245 Kexue Dadao, Huangpu District, Guangzhou, PRC. As of the Latest Practicable Date, the registered share capital of our Company is RMB20,352,428.

Our Company has established a place of business in Hong Kong at Unit 17, 6/F, Houston Centre, 63 Mody Road, Tsim Sha Tsui, Hong Kong, and has been registered as a non-Hong Kong company in Hong Kong under Part 16 of the Companies Ordinance on [•]. Mr. Ho Wai Lok has been appointed as our authorized representative for acceptance of service of process and notices in Hong Kong whose correspondence address is the same as our place of business in Hong Kong.

As our Company was established in the PRC, our corporate structure and Articles of Association are subject to the relevant laws and regulations of the PRC. A summary of the relevant provisions of our Articles of Association is set out in “Appendix V — Summary of Articles of Association”.

2. Changes in the share capital of our Company

Save as disclosed in “History, Development and Corporate Structure”, there has been no alteration in the share capital of the Company within two years immediately preceding the date of this document.

3. Changes in the share capital of our subsidiaries

Details of our subsidiaries are set out in “History, Development and Corporate Structure” and the Accountants’ Report in Appendix I to this document.

Details of the changes in the share capital of the Company’s subsidiaries within the two years immediately preceding the date of this document are set at below :

- (a) On 10 June 2025, Xinji Pharma (Zhuhai) Co, Ltd. was established as a limited liability company in the PRC with a registered capital of RMB30.0 million.
- (b) On 24 July 2024, Jiansu Hengji Medical Co., Ltd. was established as a limited liability company in the PRC with a registered capital of RMB60.0 million.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (c) On 25 November 2025, Xinji Pharma (Shaoguan) Co., Ltd. was established as a limited liability Company in the PRC with a registered capital of RMB36.0 million.
- (d) On 23 December 2025, a shareholders' resolution was passed for Guangzhou Micnano to increase its registered capital by RMB2.4 million.

Save as disclosed above, as at the Latest Practicable Date, there was no alterations of share capital of our subsidiaries within the two years immediately preceding the date of this document.

4. Resolutions of the Shareholders

- (i) Pursuant to a general meeting of the Shareholders of our Company held on 12 December 2025, the Shareholders resolved that, among others:
 - (a) the sub-division of the Shares with nominal value of RMB1.00 each on the basis of 1:5 effective from the [REDACTED], and taking into account the Share Subdivision, the issuance by our Company of the H Shares of nominal value of RMB0.20 each and such H Shares being [REDACTED] on the Stock Exchange;
 - (b) the number of H Shares to be issued shall not be more than [REDACTED]% of the total issued share capital of our Company as enlarged by the [REDACTED] (without taking into account of any H Shares which may be issued upon the exercise of the [REDACTED]), and the grant to the [REDACTED] (or their representatives) of the [REDACTED] of not more than 15% of the number of H Shares issued under the [REDACTED];
 - (c) the conditional adoption of the Articles of Association, which shall become effective on the [REDACTED], and the authorisation of the Board to amend the Articles of Association in accordance with relevant laws and regulations and upon the request from the Stock Exchange and relevant PRC regulatory authorities; and
 - (d) authorization of the Board or its authorized individual(s) to handle all matters relating to, among other things, the [REDACTED], the issue and [REDACTED] of the H Shares on the Stock Exchange.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by members of our Group within the two years immediately preceding the date of this document, and are or may be material:

- (a) capital contribution agreement dated July 23, 2024 entered into among (1) Dr. Wu, Guangzhou Yuexiu Redhill Venture Capital Fund Partnership (L.P.) (廣州越秀區丹麓創業投資基金合夥企業(有限合夥)) (“**Yuexiu Redhill**”), Guangzhou Shanji Investment Consulting Partnership (Limited Partnership)* (廣州市善濟投資諮詢企業(有限合夥)) (“**Shanji Investment**”), Guangzhou Guangji Investment Biopharmaceutical Investment Enterprise (Limited Partnership)* (廣州廣濟生物醫藥投資合夥企業(有限合夥)) (“**Guangji Investment**”), Guangzhou Minji Investment Consulting Co., Ltd.* (廣州民濟投資諮詢有限公司) (“**Minji Investment**”), Guangzhou Deji Investment Consulting Partnership (Limited Partnership)* (廣州德濟投資諮詢合夥企業(有限合夥)) (“**Deji Investment**”), Guangzhou Baiji Biopharmaceutical Investment Enterprise (Limited Partnership)* (廣州百濟生物醫藥投資合夥企業(有限合夥)) (“**Baiji Investment**”), Mr. Chen Jian (陳劍), Guangzhou Houji Investment Biopharmaceutical Investment Enterprise (Limited Partnership)* (廣州厚濟生物醫藥投資合夥企業(有限合夥)) (“**Houji Investment**”), Yangzhou Yaorongquan Venture Capital Enterprise (Limited Partnership) (揚州藥融圈創業投資合夥企業(有限合夥)) (“**Yangzhou Yaorongquan**”), Mr. Kong Zhenyong (孔鎮勇), Mr. Zhang Jun (張軍), Yujiang Yunsheng Enterprise Management Centre (Limited Partnership)* (余江縣允升企業管理中心(有限合夥)) (“**Yujiang Yunsheng**”), Guangzhou Fengbang Consulting Co., Ltd.* (廣州豐邦諮詢有限公司) (“**Fengbang Consulting**”); and (2) Lianyungang Economic and Technological Development Area Xinchengxin Medical Investment Partnership (Limited Partnership) 連雲港經濟技術開發區新誠新醫藥投資合夥企業(有限合夥) (“**Xincheng New Medical**”), Lianyungang Jinkong Modern Services Investment Fund Partnership (Limited Partnership)* 連雲港市金控現代服務業投資基金合夥企業(有限合夥) (“**Jinkong Modern**”), pursuant to which Xincheng New Medical and Jinkong Modern agreed to subscribe for the registered capital of RMB1,441,717 of the Company at an aggregate consideration of RMB50,000,000, where Xincheng New Medical agreed to subscribe for RMB865,030 of the registered capital at a consideration of RMB30,000,000; and Jinkong Modern agreed to subscribe for RMB576,687 of the registered capital at a consideration of RMB20,000,000;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (b) capital contribution agreement dated December 23, 2024 entered into among (1) Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern; and (2) Zhejiang Venture Capital Group Co., Ltd.* (浙江省創業投資集團有限公司) (“**Zhejiang VC**”) and Zhuhai Fund III Venture Capital Partnership (Limited Partnership)* (珠海基金三期創業投資合夥企業(有限合夥)) (“**Zhuhai Fund III**”), pursuant to which Zhejiang VC and Zhuhai Fund III agreed to subscribe for the registered capital of RMB1,730,060 of the Company at an aggregate consideration of RMB60,000,000, where Zhejiang VC agreed to subscribe for RMB865,030 of the registered capital at a consideration of RMB30,000,000; and Jinkong Modern agreed to subscribe for RMB865,030 of the registered capital at a consideration of RMB30,000,000;
- (c) capital contribution agreement dated June 26, 2025 entered into among (1) Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern, Zhejiang VC and Zhuhai Fund III; and (ii) Guangzhou Guangyao Industry Investment Venture Capital Fund Partnership (Limited Partnership)* (廣州廣藥產投創業投資基金合夥企業(有限合夥)) (“**Guangyao VC**”), Mr. Chu Xianfu (褚先富) and Mr. Pan Lu (潘璐), pursuant to which Guangyao VC, Mr. Chu and Mr. Pan agreed to subscribe for RMB1,153,374 of the Company at an aggregate consideration of RMB40,000,000, where Guangyao VC agreed to subscribe for RMB865,030 of the registered capital at a consideration of RMB30,000,000; Mr. Chu agreed to subscribe for RMB144,172 of the registered capital at a consideration of RMB5,000,000; and Mr. Pan agreed to subscribe for RMB144,172 of the registered capital at a consideration of RMB5,000,000;
- (d) capital contribution agreement dated August 7, 2025 entered into among (1) Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern, Zhejiang VC, Zhuhai Fund II, Guangyao VC, Mr. Chu Xianfu and Mr. Pan Lu; and (ii) Yueyang Haiyer Pharmaceutical Investment Partnership (Limited Partnership)* (岳陽市海耶爾醫藥產業投資合夥企業(有限合夥)) (formerly known as Yueyang Caijin Haiyer Taiyi Industry Investment Partnership (Limited Partnership)* 岳陽市財金海耶爾泰益產業投資合夥企業(有限合夥)) (“**Yueyang LP**”), pursuant to which Yueyang LP agreed to subscribe for RMB1,153,374 of the registered capital of the Company at an aggregate consideration of RMB40,000,000;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (e) capital increase agreement dated November 25, 2025 entered into among (1) Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern, Zhejiang VC, Zhuhai Fund II, Guangyao VC, Mr. Chu Xianfu, Mr. Pan Lu, Yueyang LP; and (2) Shaoguan Shoujiantou Venture Capital Partnership (LP) (韶關市首建投創業投資基金合夥企業(有限合夥)) (“**Shaoguan LP**”), pursuant to which Shaoguan LP agreed to subscribe RMB399,067 of the registered capital of the Company at an aggregate consideration of RMB30,000,000;
- (f) shareholders’ agreement dated November 25, 2025 entered into among Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern, Zhejiang VC, Zhuhai Fund II, Guangyao VC, Mr. Chu Xianfu, Mr. Pan Lu, Yueyang LP and Shaoguan LP, pursuant to which the shareholders’ rights were agreed among the parties;
- (g) supplemental agreement dated November 25, 2025 to the shareholders’ agreement dated November 25, 2025 entered into among Dr. Wu, Yuexiu Redhill, Shanji Investment, Guangji Investment, Minji Investment, Deji Investment, Baiji Investment, Mr. Chen Jian, Mr. Kong Zhenyong, Mr. Zhang Jun, Houji Investment, Yangzhou Yaorongquan, Yujiang Yunsheng, Fengbang Consulting, Xincheng New Medical, Jinkong Meodern, Zhejiang VC, Zhuhai Fund II, Guangyao VC, Mr. Chu Xianfu, Mr. Pan Lu, Yueyang LP and Shaoguan LP, pursuant to which the shareholders’ rights and termination of special rights of the shareholders were agreed among the parties; and
- (h) the [REDACTED].

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

2. Intellectual Property Rights of Our Group




(a) Trademarks

As of the Latest Practicable Date, our Group has registered the following trademarks which, in the opinion of our Directors, are material to our business:

No.	Trademark	Registration number	Class	Name of Registered Proprietor	Place of Registration	Date of Registration	Expiry Date
1.		82190959	42	Our Company	PRC	June 7, 2025	June 6, 2035
2.		74346958	35	Our Company	PRC	April 7, 2024	April 6, 2034
3.		73695591	5	Our Company	PRC	March 7, 2024	March 6, 2034
4.		73537206	5	Our Company	PRC	February 14, 2024	February 13, 2034
5.		73541699	5	Our Company	PRC	February 14, 2024	February 13, 2034
6.		70810668	42	Our Company	PRC	May 7, 2024	May 6, 2034
7.		65121672	35	Our Company	PRC	February 14, 2023	February 13, 2033
8.		65134682	5	Our Company	PRC	February 14, 2023	February 13, 2033
9.		65427250	40	Our Company	PRC	January 7, 2023	January 6, 2033
10.		65423700	40	Our Company	PRC	January 7, 2023	January 6, 2033

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Registration number	Class	Name of Registered Proprietor	Place of Registration	Date of Registration	Expiry Date
11.		65400498	42	Our Company	PRC	January 7, 2023	January 6, 2033
12.	ASTMT	65136059	5	Our Company	PRC	January 14, 2023	January 13, 2033
13.	VMAP	65133739	5	Our Company	PRC	December 28, 2022	December 27, 2032
14.	ASTMT	65133385	10	Our Company	PRC	December 14, 2022	December 13, 2032
15.	VMAP	65129216	3	Our Company	PRC	December 28, 2022	December 27, 2032
16.	VMAP	65120915	10	Our Company	PRC	December 14, 2022	December 13, 2032
17.		65482031	42	Our Company	PRC	December 21, 2022	December 20, 2032
18.		65480516	40	Our Company	PRC	December 21, 2022	December 20, 2032
19.	AQMS	65115989	3	Our Company	PRC	December 21, 2022	December 20, 2032
20.	VMAP	65115233	44	Our Company	PRC	December 14, 2022	December 13, 2032
21.	ASTMT	65113402	44	Our Company	PRC	December 14, 2022	December 13, 2032


APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Registration number	Class	Name of Registered Proprietor	Place of Registration	Date of Registration	Expiry Date
22.		65113339	44	Our Company	PRC	December 14, 2022	December 13, 2032
23.		39110120	5	Our Company	PRC	March 28, 2020	March 27, 2030
24.		38847663	5	Our Company	PRC	February 7, 2020	February 6, 2030
25.		36891599	42	Our Company	PRC	January 28, 2020	January 27, 2030
26.		35893215	42	Our Company	PRC	September 7, 2019	September 6, 2029
27.		35881971	42	Our Company	PRC	September 7, 2019	September 6, 2029
28.		34396950	5	Our Company	PRC	August 28, 2019	August 27, 2029
29.		34392732	35	Our Company	PRC	August 28, 2019	August 27, 2029
30.		34379043	42	Our Company	PRC	September 7, 2019	September 6, 2029
31.		33381271	42	Our Company	PRC	July 7, 2019	July 6, 2029

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Registration number	Class	Name of Registered Proprietor	Place of Registration	Date of Registration	Expiry Date
32.		27293579	42	Our Company	PRC	November 7, 2018	November 6, 2028
33.	新济	18318560	40	Our Company	PRC	December 21, 2016	December 20, 2026
34.	新济	18318552	42	Our Company	PRC	December 21, 2016	December 20, 2026

(b) Patents

As of the Latest Practicable Date, our Group had registered the following patents which, in the opinion of our Directors, were material to our business:

No.	Description	Type	Registration Place	Patent Number	Name of Registered Proprietor	Application Date	Authorization Announcement Date
1.	A kind of levodopa nasal spray and its preparation method and application 一種左旋多巴鼻噴霧劑及其製備方法及應用	Invention	PRC	ZL202311494072.1	Our Company	November 9, 2023	November 22, 2024
2.	Rivastigmine nasal spray and its preparation method 卡巴拉汀鼻噴霧劑及其製備方法	Invention	PRC	ZL202211255974.5	Our Company	October 13, 2022	August 11, 2023

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
3.	Biom mineralized liposomes co-loaded with dihydroartemisinin and calcium phosphate, preparation method and application 共載雙氫青蒿素及磷酸鈣的生物礦化脂質體及其製備方法和應用	Invention	PRC	ZL202210715997.3	Our Company	June 22, 2022	July 7, 2023
4.	Rizatriptan nasal spray and preparation method thereof 利扎曲普坦鼻噴霧劑及其製備方法	Invention	PRC	ZL202210541760.8	Our Company	May 17, 2022	February 3, 2023
5.	Polymyxin sulfate B/raffinose dry powder and its inhalation powder aerosol and preparation method 硫酸多粘菌素B/棉子糖乾粉及其吸入粉霧劑和製備方法	Invention	PRC	ZL202210061115.6	Our Company	January 19, 2022	September 2, 2022
6.	Moisture-proof and moisture-resistant low-density carrier particles and their preparation methods and applications 防潮抗濕的低密度載體顆粒及其製備方法和應用	Invention	PRC	ZL201611185899.4	Our Company	December 20, 2016	October 13, 2020
7.	Carrier particles with porous structure and their preparation methods and applications 多孔結構的載體顆粒及其製備方法和應用	Invention	PRC	ZL201611124085.X	Our Company	December 8, 2016	September 20, 2019

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
8.	Particles with surface nanoscale rough structures and their preparation methods and applications 表面納米級粗糙結構的顆粒及其製備方法和應用	Invention	PRC	ZL201610013832.6	Our Company	January 7, 2016	November 9, 2018
9.	Nitroglycerin coating, nitroglycerin sublingual tablets and their preparation methods 硝酸甘油包覆物、硝酸甘油舌下片及其製備方法	Invention	PRC	ZL202210475629.6	Our Company	April 29, 2022	May 5, 2023
10.	A simvastatin pulse-release tablet and its preparation method 一種辛伐他汀脈衝釋放片及其製備方法	Invention	PRC	ZL202011165049.4	Our Company	October 27, 2020	December 13, 2022
11.	Rapidly separating soluble microneedles and their preparation methods 快速分離型可溶性微針及其製備方法	Invention	PRC	ZL201811022455.8	Our Company	September 3, 2018	April 1, 2022
12.	Metformin hydrochloride enteric-coated tablets and their preparation method 鹽酸二甲雙胍腸溶片及其製備方法	Invention	PRC	ZL202010871918.9	Our Company	August 26, 2020	August 17, 2021

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
13.	Lycedar alkali methane sustained-release micropellet coating granules, sustained-release micropellet tablets and their preparation methods 石杉碱 甲缓释微丸包衣颗粒、缓释 微丸片及其制备方法	Invention	PRC	ZL201710681815.4	Our Company	August 10, 2017	October 16, 2020
14.	Octreotide acetate dry powder inhalation preparation and method of its preparation 醋酸奥曲肽干粉吸入制剂及 其制备方法	Invention	PRC	ZL201611141634.4	Our Company	December 12, 2016	October 13, 2020
15.	Cubic liquid crystal gel injection of local anesthetic and its preparation method 局部麻醉药的立方液晶原位 凝胶注射剂及其制备方法 .	Invention	PRC	ZL201611131813.X	Our Company	December 9, 2016	January 21, 2020
16.	Thymic pentapeptide soluble microneedles and their preparation method 胸腺五 肽可溶性微针及其制备方 法	Invention	PRC	ZL201710393418.7	Our Company	May 27, 2017	January 7, 2020
17.	Thiamolol maleate cubic liquid crystal nanoparticle eye drops and preparation method thereof 马来酸噻吗 洛尔立方液晶纳米粒滴眼液 及其制备方法	Invention	PRC	ZL201611227982.3	Our Company	December 27, 2016	September 20, 2019

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
18.	Liquid crystal nanoparticle precursor particles, self-assembled liquid crystal nanoparticles and their preparation methods 液晶納米粒前體微粒、自組裝液晶納米粒及其製備方法	Invention	PRC	ZL201610887832.9	Our Company	October 11, 2016	June 18, 2019
19.	Itraconazole inhalation powder aerosol and its preparation method 伊曲康唑吸入粉霧劑及其製備方法	Invention	PRC	ZL201410597457.5	Our Company	October 29, 2014	November 24, 2017
20.	Precursor suspension of soluble liquid crystals and preparation method thereof 溶致液晶的前體混懸液及其製備方法	Invention	PRC	ZL201210585633.4	Our Company	December 28, 2012	November 5, 2014
21.	Netimicin sulfate inhalation powder aerosol and its preparation method 硫酸奈替米星吸入粉霧劑及其製備方法	Invention	PRC	ZL201210457832.7	Our Company	November 14, 2012	November 5, 2014
22.	A semaglutide soluble microneedle composition and a method of preparation thereof 一種司美格魯肽可溶性微針組合物及其製備方法	Invention	PRC	ZL202210162729.3	Our Company	February 22, 2022	September 19, 2023
23.	Folic acid tablets and how they are prepared 葉酸片及其製備方法	Invention	PRC	ZL202210681656.9	Our Company	June 15, 2022	September 12, 2023

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
24.	Whitening and freckle removal compositions, whitening and freckle removal soluble microneedle patches and their preparation methods 美白祛斑組合物、美白祛斑可溶性微針貼片及其製備方法	Invention	PRC	ZL202010961448.5	Our Company	September 14, 2020	October 4, 2022
25.	A dexmedetomidine hydrochloride soluble microneedle and its preparation method 一種鹽酸右美托咪定可溶性微針及其製備方法	Invention	PRC	ZL202210847168.0	Novaken Research	July 19, 2022	March 18, 2025
26.	A abapotide soluble microneedle patch and its preparation method 一種阿巴帕肽可溶性微針貼片及其製備方法	Invention	PRC	ZL202310406063.6	Novaken Research	April 14, 2023	October 18, 2024
27.	Microneedle transdermal drug delivery device 微針經皮給藥裝置	Utility Model	PRC	ZL202320714053.4	Our Company, Novaken Research	April 3, 2023	April 2, 2024
28.	A dispenser for microneedle introduction 一種配合微針導入用的給藥器	Utility Model	PRC	ZL202323585439.9	Our Company, Novaken Research	December 26, 2023	November 22, 2024
29.	A microneedle delivery device 一種微針給藥裝置	Utility Model	PRC	ZL202420033537.7	Our Company, Novaken Research	January 5, 2024	November 15, 2024
30.	A microneedle transdermal drug delivery device 一種微針經皮給藥裝置	Utility Model	PRC	ZL202420033523.5	Our Company, Novaken Research	January 5, 2024	September 20, 2024

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
31.	Microneedling patches for weight loss and how they are prepared 用於減肥的微針貼片及其製備方法	Invention	PRC	ZL201911342239.6	Our Company	December 23, 2019	October 4, 2022
32.	Microneedling patches for improving acne on the skin and how they are prepared 改善皮膚痤瘡的微針貼片及其製備方法	Invention	PRC	ZL201911236031.6	Our Company	December 5, 2019	February 8, 2022
33.	Microneedle patches for improving hypertrophic scars on the skin and how they are prepared 改善皮膚增生性癍痕的微針貼片及其製備方法	Invention	PRC	ZL201911223281.6	Our Company	December 3, 2019	October 29, 2021
34.	Wrinkle microneedle patches with high load macromolecular weight hyaluronic acid and/or its sodium salt particles and their preparation method 高負載大分子透明質酸和/或其鈉鹽顆粒的祛皺微針貼片及其製備方法	Invention	PRC	ZL201911149820.6	Our Company	November 21, 2019	December 16, 2022
35.	Compositions with whitening effects, whitening soluble microneedle patches with high drug loads and their preparation methods 具有美白功效的組合物、高載藥量的美白可溶性微針貼片及其製備方法	Invention	PRC	ZL201911115373.2	Our Company	November 14, 2019	April 29, 2022

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

No.	Description	Type	Registration		Name of Registered		Authorization
			Place	Patent Number	Proprietor	Application Date	Announcement Date
36.	Dexmedetomidine microneedle patch and its preparation method and application 右美托咪定微針貼劑及其製備方法和應用	Invention	PRC	ZL202411676053.5	Our Company	November 21, 2024	November 28, 2025
37.	Gel patch containing onion extract and its preparation method 含洋蔥提取物的凝膠貼膏及其製備方法.	Invention	PRC	ZL202311121766.0	Our Company	August 31, 2023	July 15, 2025
38.	Gel patch and its preparation method 凝膠貼膏劑及其製備方法	Invention	PRC	ZL202310448495.3	Our Company	April 24, 2023	October 28, 2025
39.	Rizatriptan microneedle patch and its preparation method and application 利扎曲普坦微針貼劑及其製備方法.	Invention	PRC	ZL202411901165.6	Our Company	December 20, 2024	November 4, 2025
40.	A nasal spray acting on the central nervous system and its preparation method and application 一種用作於中樞神經系統的鼻噴霧劑及其製備方法及應用	Invention	PRC	ZL202311494348.6	Our Company	Novemebr 9, 2023	July 11, 2025
41.	Semaglutide dissolving microneedle patch and its preparation method 司美格魯肽可溶性微針貼片及其製備方法	Invention	PRC	ZL202210028787.7	Our Company	January 11, 2022	August 1, 2023

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(c) Domain names

As at the Latest Practicable Date, our Group has registered the following domain name which, in the opinion of our Directors, is material to our business:

No.	Domain Name	Registered Owner	Registration Date	Expiry Date
1.	novaken.cn	Our Company	April 26, 2020	March 24, 2026

Save as the above, as of the Latest Practicable Date, there were no other intellectual property rights which were material to our business.

C. FURTHER INFORMATION ABOUT DIRECTORS, SENIOR MANAGEMENT AND SUBSTANTIAL SHAREHOLDERS

1. Interests and short positions of Directors and the chief executive of our Company in the Shares, underlying Shares or debentures of our Company and its associated corporations

Save as disclosed below, immediately following the completion of the [REDACTED] (having taken into account of the Share Subdivision but assuming no exercise of the [REDACTED]), so far as the Directors are aware, none of the Directors or chief executive of the Company will have any interests and/or short position (as applicable) in the Shares, underlying Shares or debentures of the Company or our associated corporation (within the meaning of Part XV of the SFO) which will be (i) required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO); or (ii) required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules to be notified to the Company and the Stock Exchange, once the H Shares are [REDACTED] on the Stock Exchange.

Interests and/or short positions in our Company

Name	Capacity/Nature of interest	Shares held immediately after the completion of the [REDACTED]	
		Number of Shares ⁽¹⁾	Approximate percentage ⁽²⁾
Dr. Wu ⁽²⁾⁽³⁾	Beneficial owner	[REDACTED] H Shares (L)	[REDACTED]

APPENDIX VI STATUTORY AND GENERAL INFORMATION

Name	Capacity/Nature of interest	Shares held immediately after the completion of the [REDACTED]	
		Number of Shares ⁽¹⁾	Approximate percentage ⁽²⁾
	Interest in controlled Corporations	[REDACTED] H Shares (L)	[REDACTED]
Dr. Pan Xin ⁽²⁾⁽³⁾	Interest of spouse	[REDACTED] H Shares (L)	[REDACTED]

(L) denotes long positions

- The calculation is based on the assumption that (i) the Share Subdivision is completed, (ii) the [REDACTED] is not exercised, (iii) the [REDACTED] Unlisted Shares (taking into account the Share Subdivision) will be converted into H Shares, and (iv) the total number of the Shares in issue will be [REDACTED] H Shares immediately after completion of the [REDACTED] (assuming the [REDACTED] is not exercised).
- Dr. Wu and Dr. Pan Xin are spouses. Accordingly, Dr. Wu and Dr. Pan Xin are deemed to be interested in the Shares held by each other by virtue of Part XV of the SFO.
- Dr. Wu is deemed to be interested in (1) the approximately 8.68% Shares owned by Guangzhou Shanji Investment Consulting Partnership (Limited Partnership) (“**Shanji Investment**”) (a limited partnership which Dr. Wu is its general partner); (2) the approximately 6.03% Shares owned by Guangji Investment (a limited partnership which Dr. Wu is its general partner); (3) the approximately 5.43% Shares owned by Guangzhou Deji Investment Consulting Partnership (Limited Partnership) (a limited partnership which Dr. Wu is its general partner); (4) the approximately 5.43% Shares owned by Guangzhou Minji Investment Consulting Co., Ltd. (a company controlled by Dr. Wu); and (5) the approximately 2.29% Shares owned by Guangzhou Baiji Biopharmaceutical Investment Enterprise (Limited Partnership) (a limited partnership which Dr. Wu is its general partner) by virtue of Part XV of the SFO.

Interests and/or short positions in associated corporations

Name of Shareholder	Capacity/Nature of interest	Associated corporations	Shares/equity interest held
Dr. Wu	Beneficial owner ⁽¹⁾	Novaken Pharma (Zhuhai Hengqin) Co., Ltd.	Approximate percentage ⁽²⁾ 35%

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Note:

1. Novaken Pharma (Zhuhai Hengqin) Co., Ltd. is a limited liability company established in the PRC owned as to 65% by our Company and 35% by Dr. Wu.

2. Interests and/or short positions of substantial Shareholders in the Shares or underlying Shares of our Company and its associated corporations

So far as is known to our Directors, immediately following completion of the [REDACTED] (having taken into account of the Share Subdivision but assuming no exercise of the [REDACTED]), the following persons (not being a Director or chief executive of our Company) will have an interest or a short position in the Shares or underlying Shares of our Company and its associated corporations which would fall to be disclosed to our Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other members of our Group:

APPENDIX VI STATUTORY AND GENERAL INFORMATION

Interests and/or short positions in our Company

Name of Shareholder	Capacity/Nature of interest	Shares held immediately after the completion of the [REDACTED]	
		Number of Shares ⁽¹⁾	Approximate percentage ⁽²⁾
Guangzhou Yuexiu Redhill Venture Capital Fund Partnership (L.P.) ("Yuexiu Redhill").	Beneficial owner	[REDACTED] H Shares (L)	[REDACTED]
Shanji Investment	Beneficial owner	[REDACTED] H Shares (L)	[REDACTED]

Notes:

(L) denotes long positions

- The calculation is based on the assumption that (i) the Share Subdivision is completed, (ii) the [REDACTED] is not exercised, (iii) the [REDACTED] Unlisted Shares (taking into account the Share Subdivision) will be converted into H Shares, and (iv) the total number of the Shares in issue will be [REDACTED] H Shares immediately after completion of the [REDACTED] (assuming the [REDACTED] is not exercised).

3. Particulars of Directors’ Service Contracts and Appointment Letters

Each of the Directors [has entered] into a service contract or a letter of appointment with our Company.

Save as disclosed above, we have not entered into, and do not propose to enter into any service contracts or letters of appointment with any of our Directors in their respective capacities as Directors (excluding agreements expiring or determinable by any member of our Group within one year without payment of compensation other than statutory compensation).

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

The remuneration of Directors is determined by our Company with reference to the duties and level of responsibilities of each Director, the remuneration policy of our Company and the prevailing market conditions.

The appointments of our Directors are subject to the provisions of retirement by rotation of directors under the Articles of Association.

4. Remuneration of Directors

Save as disclosed in "Directors and Senior Management" and Notes 9 and 10 to the Accountants' Report set out in Appendix I for the Track Record Period, none of our Directors received other remunerations or benefits in kind from us.

5. Agency Fees or Commissions Received

Save as disclosed in the paragraph headed "[REDACTED]" in this document, within the two years immediately preceding the date of this document, no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of its subsidiaries.

6. Disclaimers

Save as disclosed this document:

- (a) none of our Directors or our chief executive has any interest or short position in our Shares, underlying Shares or debentures of our Company or any of our associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to us and the Stock Exchange pursuant to Model Code for Securities Transactions by Directors of [REDACTED] Issuers once the H Shares are [REDACTED] on the Stock Exchange;
- (b) none of our Directors is aware of any person (not being a Director or chief executive of our Company) who will, immediately following the completion of the [REDACTED] (without taking into account any H Shares which may be allotted and issued pursuant to the exercise of the [REDACTED]), have an interest or short position in our

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Shares or underlying Shares which would fall to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO or who is interested, directly or indirectly, in 10% or more of the issued voting shares of any member of our Group;

- (c) save in connection with the [REDACTED], none of the Directors nor any of the experts referred to “Qualifications of Experts” below is (i) materially interested in any contract or arrangement subsisting at the date of this document which is interested legally or beneficially in any shares in any member of the Group; or (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of the Group; and
- (d) none of our Directors or any of the parties listed in “Qualifications of Experts” in this Appendix:
 - i. has been interested in our promotion, or in any assets which have been, within two years immediately preceding the date of this document, acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to any member of our Group; or
 - ii. materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business.

D. OTHER INFORMATION

1. Pre-[REDACTED] Equity Incentive Scheme

The following is a summary of the principal terms of the employee incentive scheme adopted by our Company in August 2025 (i.e. the Pre-[REDACTED] Equity Incentive Scheme). For details of the Pre-[REDACTED] Equity Incentive Scheme, please refer to “History, Development and Corporate Structure — Employee Incentive Platform” in this document.

The terms of the Pre-[REDACTED] Equity Incentive Scheme are not subject to the provisions of Chapter 17 of the Listing Rules as no stock will be granted under the Pre-[REDACTED] Equity Incentive Scheme after the Listing. All awards under the Pre-[REDACTED] Equity Incentive Scheme have been fully granted.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(a) Purpose

The Pre-[REDACTED] Equity Incentive Scheme aims to, among other things, motivate the company's core employees and enhance their enthusiasm, sense of belonging, responsibility, and mission; attract and retain talent; and encourage diligence and commitment in achieving the company's strategic objectives.

(b) Participants of the Pre-[REDACTED] Equity Incentive Scheme

Eligible participants of the Pre-[REDACTED] Equity Incentive Scheme (the "Participant(s)") are principally core management members and employees of our Group, which shall be determined by the management of our Company from time to time on factors such as the contribution, position and years of service, conduct of the Participants.

(c) Maximum number of incentive Shares

The incentive Shares under the Pre-[REDACTED] Equity Incentive Scheme refer to the equity already held by Guangji Investment, corresponding to RMB1,227,069 in the registered capital of the Company and representing approximately 6.03% of the total issued share capital of our Company immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised).

(d) Grant price and grant of incentive Shares

The grant price per Share under the Pre-[REDACTED] Equity Incentive Scheme is RMB16.45, based on the valuation of our Company before increase of its registered capital by Guangji Investment. Participants may subscribe for the incentive Shares by signing partnership agreement and supplementary agreement, paying the grant price within a specific period and becoming a limited partner of the Employee Incentive Platform. Participants shall be entitled to the property rights corresponding to the incentive Shares (including but not limited to the rights to receive dividends and proceeds from transfer but excluding governance rights such as voting or making proposals which are exercised by the general partner) proportionate to their indirect shareholding through the Employee Incentive Platform.

(e) Lock-up period

After [REDACTED], participants will be subject to such lock-up periods as may be required under the applicable laws, regulatory rules and exchange rules. Under the PRC Company Law, a Participant who is a director or senior management of the Company is subject to lock-up period

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(the "**Lock-up Period**") of one year from the date of [REDACTED], and after the Lock-up Period, is subject to an annual transfer limit of up to 25% of shares owned by himself or herself and a transfer restriction of 6 month after resignation.

Participants shall not transfer directly; create pledges, entrustments or trusts over; or transfer income rights or engage in any other form of disguised transfer of, their partnership interest in the Employee Incentive Platform.

(f) Disposal of incentive Shares

After the Lock-up Period expires and all restrictions under the Scheme are lifted, the Participants may dispose of incentive Shares indirectly held by them through the Employee Incentive Platform by notifying the general partner in writing within the first 10 trading days of each quarter. The general partner of the Employee Incentive Platform may have a pre-emption right to buy out the Participants' partnership interest in the Employee Incentive Platform at market-equivalent value. If the general partner decided not to exercise such right, he or she may notify the remaining limited partners of the Employee Incentive Platform of the intention to dispose and the amount to be disposed. If no limited partners purchase the exiting Participants' partnership interest, the general partner may arrange for the Employee Incentive Platform to dispose of incentive Shares on the secondary market through auction, block trade, negotiated transfer, etc. and distribute the net [REDACTED] (after deducting taxes and fees) to the relevant Participants.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

(g) Repurchase of incentive Shares

The table below sets out the arrangement in relation to the repurchase of incentive Shares directly or indirectly held by the Participants under certain repurchase events:

Repurchase events (the "Repurchase Events")	Repurchase price
(1) Fault-based exit (除名) where the Participant was personally at fault for certain circumstances and was required to be withdrawn from the partnership, including: <ul style="list-style-type: none">a. obtaining eligibility for the Pre-[REDACTED] Equity Incentive Scheme through fraudulent means;b. failure to fulfill capital contribution obligations;c. resigning without the Company's approval;d. failure to meet performance standard for 2 consecutive years;e. serious violation of the policies and regulations of the Company;f. causing major loss or its affiliates as a result of intentional or gross negligence;g. conviction of crimes such as corruption, bribery, embezzlement, or subject to restriction on personal liberty affecting job performance;	The repurchase price shall be equal to the actual amount of capital contribution paid by such Participant for the incentive Shares to be repurchased.

APPENDIX VI**STATUTORY AND GENERAL INFORMATION**

Repurchase events (the "Repurchase Events")	Repurchase price
h. misappropriation of the Company's funds;	
i. opening accounts in personal name for the Company's funds;	
j. lending the Company's funds or providing guarantees without proper approval;	
k. entering into contracts or transactions with the Company without approval;	
l. exploiting position for personal gain, engaging in competing business, or misusing the Company's resources;	
m. accepting commissions from parties transacting with the Company;	
n. unauthorized disclosure of confidential information of the Company and its subsidiaries;	
o. violating other duty of loyalty and diligence owed to the Company under relevant laws, regulations and articles of association of the Company.	

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Repurchase events (the "Repurchase Events")	Repurchase price
<p>(2) No-fault exit (當然退夥) where the Participant is no longer suitable or able to continue as a partner in the Employee Incentive Platform due to objective reasons, including:</p> <ul style="list-style-type: none">a. resignation as an employee of the Company or its subsidiaries with the Company's approval or through amicable negotiation;b. death;c. loss of work capacity, missing or legally declared missing;d. being legally determined to have no or limited civil capacity;e. the Participant's partnership interests in the Employee Incentive Platform being subject to compulsory enforcement by a People's Court in the PRC.	<p>The repurchase price shall be determined as follows:</p> <ul style="list-style-type: none">(1) prior to the completion of the [REDACTED] or after the [REDACTED] but prior to the expiry of the Lock-up Period, the repurchase price shall be equal to the sum of (i) the actual amount of capital contribution paid by such Participant for the incentive Shares to be repurchased; and (ii) benchmark loan interest during the same period;(2) after the expiry of the Lock-up Period and the release of restrictions on the incentive Shares (if any), the repurchase price shall be equal to the market price of the Shares.
<p>(3) Dissolution, winding up, or liquidation of the Company</p>	<p>The repurchase price shall be the net asset value of the Company for the most recent financial year, proportionate to the equity held by the Participant when exiting.</p>

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

Repurchase events (the “Repurchase Events”)	Repurchase price
(4) Acquisition of shares of the Company by a third party prior to the [REDACTED] which may result in a change of control	<p>The repurchase price shall be determined as follows:</p> <ol style="list-style-type: none">(1) if the purchaser acquires the ultimate beneficial owner or the equity interest of the Employee Incentive Platform, the repurchase price shall be the market price paid by the purchaser (or the proportional consideration);(2) if the Participants wish to sell their shares voluntarily and there is no third party purchaser, the ultimate beneficial owner shall acquire the shares at repurchase price equal to the sum of (i) the actual amount of capital contribution paid by such Participant for the incentive Shares to be repurchased; and (ii) benchmark loan interest during the same period.
(5) Special hardship exit where the Participant withdraws from partnership due to objective practical needs (such as major family changes, serious illness, etc.) and has not triggered fault-based exit or no-fault exit	<p>The repurchase price shall be determined through negotiation between parties involved in the transfer.</p>

Details of the incentive Shares granted under the Pre-[REDACTED] Equity Incentive Scheme

As of the Latest Practicable Date, 1,227,069 incentive Shares had been granted to 47 Participants, where all incentive Shares were indirectly held by the Participants through our employee share incentive platform at consideration of RMB16.45 per Share pursuant to the Pre-[REDACTED] Equity Incentive Scheme. As of the Latest Practicable Date, all the incentive Shares under the Pre-[REDACTED] Equity Incentive Scheme were granted. The incentive Shares granted under the Pre-[REDACTED] Equity Incentive Scheme are subject to vesting period and vesting conditions which are described under the paragraph headed “(e) Lock-up Period”.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

2. Estate Duty

The Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

3. Litigation

As of the Latest Practicable Date, no member of the Group was involved in any litigation, arbitration, administrative proceedings or claims of material importance, and so far as the Directors are aware, no litigation, arbitration, administrative proceedings or claims of material importance are pending or threatened against any member of the Group.

4. Sole Sponsor

The Sole Sponsor satisfies the independence criteria applicable to sponsors under Rule 3A.07 of the Listing Rules.

The Sole Sponsor is entitled to the sponsor’s fee in the amount of USD385,000 in connection with the [REDACTED].

5. Preliminary Expenses

As of the Latest Practicable Date, our Company has not incurred any material preliminary expenses.

6. Promoter

The promoters of the Company are all of the 22 then Shareholders immediately before our conversion into a joint stock limited liability company. Within the two years immediately preceding the date of this document, no cash, securities or other benefit has been paid, allotted or given or is proposed to be paid, allotted or given to the promoters in connection with the [REDACTED] and the related transactions described in this document.

7. Taxation of holders of Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty. The current rate charged on each of the purchaser and seller is 0.1% of the consideration of or, if higher, of the fair value of the H Shares being sold or transferred. For further information in relation to taxation, see “Appendix III — Taxation and Foreign Exchange.”

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

8. Qualification of Experts

The qualifications of the experts who have given opinions or advice and/or whose names are included in this document are as follows:

<u>Name</u>	<u>Qualifications</u>
Guotai Junan Capital Limited	Licensed corporation to conduct Type 6 (advising on corporate finance) regulated activities under the SFO
Ernst & Young	Certified public accountants and registered public interest entity auditor
Sundial Law Firm	PRC Legal Advisor
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant

9. Consents of Experts

Each of the experts named in the paragraph headed “8. Qualifications of experts” above has given and has not withdrawn its respective written consent to the issue of this document with the inclusion of its view(s) and/or report(s) and/or letter(s) and/or opinion and/or legal opinion(s) (as the case may be) and references to its name included herein in the form and context in which they are included.

10. Interests of experts in our Company

As of the Latest Practicable Date, none of the experts named in the paragraph headed “8. Qualifications of experts” above had any shareholding interests in any member of our Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

11. Binding Effect

This document shall have the effect, if an application is made in pursuance of it, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

12. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong). In case of any discrepancies between the English language version and the Chinese language version of this document, the English language version shall prevail.

13. Miscellaneous

Save as disclosed in this document:

- (a) within the two years immediately preceding the date of this document:
 - (i) no share or loan capital of our Company or of any of our subsidiaries has been issued, agreed to be issued or is proposed to be issued fully or partly paid either for cash or for a consideration other than cash;
 - (ii) no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any capital of our Company or any of our subsidiaries;
 - (iii) no commission has been paid or payable (except to [REDACTED]) for subscribing or agreeing to subscribe, or procuring or agreeing to procure subscriptions, for any Shares or debentures in our Company; and
 - (iv) no founder, management or deferred shares or any debentures in our Company or any of our subsidiaries have been issued or agreed to be issued;
- (b) no share, warrant or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (c) none of the equity and debt securities of our Company is [REDACTED] or dealt with in any other stock exchange nor is any listing or permission to deal being or proposed to be sought;
- (d) our Company has no outstanding convertible debt securities or debentures;
- (e) the Company or any of its subsidiary has not issued nor agreed to issue any founder or management or deferred shares;

APPENDIX VI

STATUTORY AND GENERAL INFORMATION

- (f) our Directors confirm that, save for the expenses in connection with the [REDACTED], there has been no material adverse change in the financial or trading position or prospects of our Group since June 30, 2025 (being the date to which the latest audited consolidated financial statements of our Group were made up) and up to the date of this document;
- (g) there are no contracts for hire or hire purchase of plant to or by us for a period of over one year which are substantial in relation to our business;
- (h) there has not been any interruption in the business of our Group which may have or have had a significant effect on the financial position of our Group in the 12 months immediately preceding the date of this document;
- (i) there are no arrangements in existence under which future dividends are to be or agreed to be waived;
- (j) the Company is a joint stock limited company and is subject to the PRC Company Law; and
- (k) there is no restriction affecting the remittance of profits or repatriation of capital into Hong Kong and from outside Hong Kong.